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Background. We previously reported the association 
among donor leukocyte chimerism, apoptosis of pre-
sumedly IL-2-deficient graft-infiltrating host cells, and 
the spontaneous donor-specific tolerance induced by 
liver but not heart allografts in mice. Survival of the 
rejection-prone heart allografts in the same strain 
combination is modestly prolonged by the pretrans-
plant infusion of immature, costimulatory molecule-
(CM) deficient donor dendritic cells (DC), an effect 
that is markedly potentiated by concomitant CM 
blockade with anti-CD40L (CDI54) monoclonal anti-
body (mAb). We investigated whether the long sur-
vival of the heart allografts in the pretreated mice was 
associated with donor leukocyte chimerism and apo-
ptosis of graft-infiltrating cells, if these end points 
were similar to those in the spontaneously tolerant 
liver transplant model, and whether the pretreatment 
effect was dependent on sustained inhibition of CM 
expression of the infused immature donor DC. In ad-
dition, apoptosis was assessed in the host spleen and 
lymph nodes, a critical determination not reported in 
previous studies of either spontaneous or "treatment-
aided" organ tolerance models. 
Methods. Seven days before transplantation of 
hearts from BIO (H_2b ) donors, 2x 106 donor-derived 
immature DC were infused i.v. into C3H (H_2k) recipi-
ent mice with or without a concomitant i.p. injection 
of anti-CD40L mAb. Donor cells were detected post-
transplantation by immunohistochemical staining for 
major histocompatibility complex class II (I-A b) in the 
cells of recipient lymphoid tissue. CM expression was 
determined by two-color labeling. Host responses to 
donor alloantigen were quantified by mixed leukocyte 
reaction, and cytotoxic T lymphocyte (CTL) assays. 
Apoptotic death in graft-infiltrating cells and in areas 
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of T -dependent lymphoid tissue was visualized by ter-
minal deoxynucleotidyltransferase-catalyzed dUTP· 
digoxigenin nick-end labeling and quantitative spec-
trofluorometry. Interleukin-2 production and localiza-
tion were estimated by immunohistochemistry. 
Results. Compared with control heart transplanta-
tion or heart transplantation after only DC adminis-
tration, concomitant pretreatment with immature do-
nor DC and anti-CD40L mAb caused sustained 
elevation of donor (I-Ab +) cells (microchimerism) in 
the spleen including T cell areas. More than 80% of the 
I-A b+ cells in combined treatment animals also were 
CD86+, reflecting failure of the mAb to inhibit CD401 
CD80/CD86 up-regulation on immature DC in vitro af-
ter their interaction with host T cells. Donor-specific 
CTL activity in graft-infiltrating cells and spleen cell 
populations of these animals was present on day 8, but 
decreased strikingly to normal control levels by day 
14. The decrease was associated with enhanced apo-
ptosis of graft-infiltrating cells and of cells in the 
spleen where interleukin-2 production was inhibited. 
The highest levels of splenic microchimerism were 
found in mice with long surviving grafts (> 100 days). 
In contrast, CTL activity was persistently elevated in 
control heart graft recipients with comparatively low 
levels of apoptotic activity and high levels of interleu-
kin-2. 
Conclusion. The donor-specific acceptance of rejec-
tion-prone heart allografts by recipients pretreated 
with immature donor DC and anti-CD40L mAb is not 
dependent on sustained inhibition of donor DC CM 
(CD86) expression. Instead, the pretreatment facili-
tates a tolerogenic cascade similar to that in sponta-
neously tolerant liver recipients that involves: (1) chi-
merism-driven immune activation, succeeded by 
deletion of host immune responder cells by apoptosis 
in the spleen and allograft that is linked to interleu-
kin-2 deficiency in both locations and (2) persistence 
of comparatively large numbers of donor-derived leu-
kocytes. These tolerogenic mechanisms are thought to 
be generic, explaining the tolerance induced by allo-
grafts spontaneously, or with the aid of various kinds 
of immunosuppression. 
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Transplantation Institute. W1540C Biomedical Science Tower. Uni-
versity of Pittsburgh Medical Center. 200 Lothrop Street, Pitts-
burgh, PA 15213. 
Compelling evidence has been summarized elsewhere that 
organ and bone marrow allograft "acceptance" are related 
forms of acquired tolerance that are not fundamentally dif-
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ferent than the tolerance induced by noncytopathic microor-
ganisms (ll. With both varieties of transplantation, coexist-
ing donor and recipient immune cells undergo reciprocal 
activation followed by various levels of mutual antigen-spe-
cific clonal exhaustion-deletion, the maintenance of which in 
the organ recipient depends on persistence of the donor leu-
kocytes (microchimerism) (2-4). Verification of this concept 
has been greatly facilitated by the use of rodent models, in 
which tolerance occurs spontaneously (5), most commonly 
involving transplantation of the leukocyte-rich liver (6-12). 
We recently showed in such a mouse liver transplant tol-
erance model that the clonal deletion associated with im-
mune activation was largely due to apoptosis of cytotoxic T 
lymphocytes (CTL)* (13). The apoptosis in graft-infiltrating 
cells (GIC) reached a peak between days 7 and 14, effectively 
forestalling rejection and eventually eliminating most of the 
antigraft CTL. Although low but significant CTL activity 
could still be detected in the allografts and host spleens at 
150 days, such liver recipients are stable thereafter (7). The 
programed cell death of CTL was inhibited by administration 
of interleukin-(lL)2 (13), with consequent increased hepato-
cyte destruction. Similar findings have been reported in a 
spontaneously tolerant rat model of liver (or composite liver/ 
intestinal) transplantation (14). In our investigation (13) and 
in that of Meyer et al. (14), apoptosis was not detennined in 
the host lymphoid organs where "high dose" clonal exhaus-
tion-deletion has been described (11). 
In our investigation using a mouse strain combination in 
which livers but not hearts reliably induce tolerance (13), the 
mechanisms of engraftment of the less tolerogenic heart al-
lografts were studied after the preoperative administration 
of an immunosuppressant with a known molecular target, in 
combination with adjunct infusions of well-characterized do-
nor leukocytes. The heart recipients were pretreated with a 
monoclonal antibody (mAb) directed against the CD40 ligand 
(CD40L, CD154) that is expressed by activated T cells. The 
adjunct cells given concomitantly were donor-derived imma-
ture DC that have a phenotype resembling interstitial DC 
resident within nonlymphoid tissue (e.g., heart or liver) (15) 
and are known to have low immunogenicity that is associated 
with poor B7 expression (16). Given alone, a single pretrans-
plant i.v. infusion of these immature donor cells (propagated 
either from liver or bone marrow) on day -7 modestly pro-
longs the survival of pancreatic islet (17) and cardiac allo-
grafts (18). This minor therapeutic effect is dramatically 
enhanced with the concomitant i.p. administration on day -7 
of anti-CD40L mAb, allowing consistently long or indefinite 
survival of normally rejection-prone cardiac allografts (16). 
The principal objective of our studies was to determine if 
* Abbreviations: CML, cell-mediated lymphocytotoxicity; Ab, an-
tibody; APC, antigen-presenting cell; BlO, C57BUlOJ; BM, bone 
marrow; C3H, C3HJHeJ; CDC, complement-dependent cytotoxicity; 
CM, costimulatory molecule(s); CTL, cytotoxic T lymphocyte; 
CTLA4, cytotoxic T lymphocyte antigen 4; DC, dendritic cell; FITC, 
fluorescein isothiocyanate; GIC, graft-infiltrating cell; GM-CSF, 
granulocyte-macrophage colony-stimulating factor; HBSS, Hanks' 
balanced salt solution; IL, interleukin; mAb, monoclonal antibody; 
MHC, major histocompatibility complex; MLR, mixed leukocyte re-
action; MST, median survival time; NPC, nonparenchymal cell; r, 
recombinant; RT, room temperature; TGF/3, transforming growth 
factor-/3; Th, T helper; TUNEL, terminal deoxynucleotidyl trans-
ferase-catalyzed dUTP-digoxigenin nick-end labeling. 
the heart allograft acceptance under these therapeutically 
altered conditions occurred by the same chimerism ~d ap-
optosis-associated mechanisms as with spontaneous hv~~ al-
lograft acceptance. This appeared to be true. I~ addltlOn, 
apoptosis in the host lymphoid tissues was determmed usmg 
the spleen as the prototype lymphoid organ. This revealed 
programed cell death in the spleen at least equal to that In 
the heart grafts. 
MATERIALS AND METHODS 
Mice. Male C57BUIOJ (BI0; H_2b), C3HJHeJ (C3H; H_Zk). and 
BALB/c (H_2d ) mice were purchased from The Jackson Laboratory 
(Bar Harbor, ME). They were maintained in the specific pathogen-
free facility of the University of Pittsburgh Medical Center, provided 
with Purina Rodent Chow (Ralston Purina, St. Louis, MOl and tap 
water ad libitum, and used at 8-12 wk old. 
Anti·CD40L mAb. MISS, a rat IgG mAb specific for mouse CD40L 
(CD154) was provided by the Immunex Corporation, Seattle WA. It 
was administered i.p. (200 p.g) as a single injection. 
Heterotopic cardiac transplantation. Fully allogeneic intraab-
dominal vascularized heart transplantation was performed from nor-
mal BlO donors to size-matched C3H recipients, as described (18). 
Graft survival was assessed by daily transabdominal palpation of the 
hearts. Rejection was determined as cessation of heartbeat, and 
confirmed histologically. 
Experimental organ transplantation protocol. Normal C3H mice 
received donor (BIO) or control syngeneic or third-party lBALB/c)-
derived immature DC, either alone or in combination with anti-
CD40L mAb (or control rat IgG). Cells (2X 106 ) were administered i.v. 
with or without anti-CD40L mAb, 7 days before BI0 heart trans-
plantation on day O. On days 0, 7, and 14 posttransplant, groups of 
mice were killed. Spleens and heart grafts were examined by immu-
nohistochemical staining for donor major histocompatibility complex 
(MHC) class II, and B7 molecule expression, and by terminal deoxy-
nucleotidyl transferase-catalyzed dVTP-digoxigenin nick-end label-
ing (TUNEL) staining for apoptotic cells. At the same times (days 7 
and 14), antidonor CTL activity of both GIC and spleen cells was 
determined. 
Propagation and purification of BM-derived myeloid dendritic 
cells (DC). BM cells harvested from femurs of normal BIO or control 
strain mice were cultured in 24-well plates (2X 1061well) in 2 ml of 
RPMI-1640 (Life Technologies, Gaithersburg, MD) supplemented 
with antibiotics, and 10% v/v fetal bovine serum (referred to subse-
quently as complete medium), 4 ng/ml recombinant (r) mouse gran· 
ulocyte-macrophage colony-stimulating factor (GM-CSF), and either 
1000 Vlml r mouse IL-4 (both cytokines from Schering Plough, Ke-
nilworth, NJ), or r human transforming growth factor /3 (TGF/3)1 (0.2 
ng/ml; R&D Systems Inc., Minneapolis, MN). The culture and 
selection procedures used to generate and purify the DC were similar 
to those reported initially by Inaba et a!. (19) and modified as 
described (16, 20). 
Flow cytometry of cultured cells. Cell surface molecule expression 
was analyzed by cytofluorography, using an EPICS ELITE flow 
cytometer (Coulter Corporation, Hialeah, FL). Staining with primary 
rat or hamster mAbs, including antibodies (Abs) directed against 
mouse dentric cell-CDC) restricted (CDllc and DEC205) and myeloid 
lineage markers (CDllb and F4ISO), and rat anti-mouse CD40, CD80 
<B7-l), or CDS6 (B7-2l (PharMingen, San Diego, CAl was followed by 
fluorescein isothiocyanate-(FITC) conjugated goat anti-rat IgG2a, or 
goat anti-hamster Ig, as described (20), MHC class II <I_Ab ) staining 
was performed using biotin-conjugated mouse anti-mouse mAbs, 
with FITC streptavidin as the secondary reagent (8). 
T cell allostimulatory activity. One-way mixed leukocyte reaction 
(MLR) cultures were established in 96-well, round-bottom microcul-
ture plates (Corning, Corning, NY\. Graded doses of l'-irradiated 
syngeneic (C3H) or allogeneic (BlO) stimulator cells were added to 1 
or 2xI05 nylon wool-eluted C3H spleen cells used as responders (8l. 
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Cultures were maintained for 72 hr; raHlTdR (1 !J.Ci/welll was added 
for the fmal 18 hr, and incorporation of [3HlTdR into DNA assessed 
by liquid scintillation counting. Results were expressed as mean 
counts per minute (cpm)= 1 SD. 
Isolation of GlC. Animals were perfused in situ via the left ven-
tricle with 30 ml collagenase type IV (0.1 mg/ml; Sigma Chemical 
Co., St. Louis, MOl. Heart grafts from experimental or control groups 
(three mice per group) were pooled, diced, and further digested in 
collagenase (1 mglml) at 37°C for 30 min. This was followed by 
Percoll (Sigma) centrifugation, as described previously for the isola-
tion of nonparenchymal cells (J 8). The cells between the top (digested 
parenchymal/myocardial cells) and the lower (erythrocyte) layers 
were collected, washed, and the number adjusted to 5 x 106 ml in 
RPMI-1640 complete medium. 
Cell-mediated lymphocytotoxicity (CML) assay. Freshly isolated 
normal heart nonparenchymai cells, heart graft-infiltrating cells, or 
spleen cells were used as effectors. The EL4 (H-2b ) lymphoma cell 
line [TIB39; American Type Culture Collection (ATCC), Rockville. 
MDI was used as a source of specific target cells. P815 (H-2d ) mouse 
mastocytoma cells (TIB64, ATCC) were used as specificity controls, 
and as lymphokine-activated killer cell targets. The target cells were 
labeled with 100 !J.Ci Na251Cr 0 4 {NEN. Life Science Products, Bos-
ton, MAJ. washed. and plated at 5x 10~ cells/well in 96-well, round-
bottomed culture plates (Corning). Serial, 2-fold dilutions of effector 
cells were added to give effector:target ratios of 100:1,50:1. and 25:l. 
in a total volume of 200 !J.I/well. The percentage of specific 5lCr 
release was determined after incubating the plates for 4 hr at 37°C 
in 5% CO2 in air. An aliquot (l00 !J.l) of supernatant was recovered 
from each well after centrifugation at 500xg for 1 min. Maximum 
"lCr release was determined by osmotic lysis of the target cells. The 
percent specific cytotoxicity was calculated using the following for-
mula: % cytotoxicity = 100 x [experimental (cpm) - spontaneous 
(cpmJlmaximum (cpm) - spontaneous (cpm)l. The results are ex-
pressed as means= 1 SD of percent specific 51Cr release in triplicate 
cultures. 
In situ nick-end labeling. DNA strand breaks were identified in 
cryostat sections (13) or in cell suspensions allowed to settle on glass 
slides (21) by terminal deoxynucieotidyl transferase-catalyzed 
dUTP-digoxigenin nick-end labeling (TUNELl. Slides were im-
mersed in 2% H20 2 for 5 min at room temperature (RT) to quench 
enuogenous peroxidase activity. They were then incubated with 20 
!J.g/ml proteinase K (Sigma) for 15 min at RT, washed in phosphate-
buffered saline. then immersed in 100 !J.l reaction buffer [0.2 Iv! 
potassium cacodylate. 25 mM Tris-HCl (pH 6.6),0.25 mglml bovine 
serum albumin. and 2.5 mM cobalt chloride] supplemented with TdT 
1.0.3 enzyme units/mil and digoxigenin-conjugated-dUTP. Each ex-
periment was performed with a negative control (without dUTP) and 
a positive control (lO-min pretreatment of slides with 1 mglml DNase 
in reaction buffer). Peroxidase-labeled Ab to digoxigenin (Oncor 
Technical Assistance. Gaithersburg, MOl was added (30 min RT), 
and the reaction developed with 3-amino-5-ethycarbizol. The slides 
were counterstained with Harris' hematoxylin, and mounted with 
Crystal mount lBiomeda Corp., Foster City, CAl. 
DNA /,ragmentation assay. DNA fragmentation in celllysates was 
determined by spectrot!uorometric assay. as described (21). 
lmmunohistochemistry. Immunohistochemical staining of tissue 
sections for donor MHC class II antigen and CM, including two-color 
labeling, was performed as described (18,22). 
Statistical analyses. Results are expressed as meanszl SD. Sta-
tistical analyses were performed using the Student's t test. or the 
~Iann \Vhitney U test. as appropriate. 
RESULTS 
Surface immunophenotype and allostimulatory activity of 
EM-derived cells propagated in GM-CSF+TGF{31 (immature 
DC) or GM-CSF+IL-4 (mature DC). Low buovant density 
cells were propagated from normal BI0 mouse- BM in GM-
CSF plus either TGF131 or IL-4 to obtain immature or mature 
myeloid DC, respectively. The cells were harvested at day 5, 
stained for surface expression of lineage-restricted and other 
antigens using an extensive panel of mAbs, and analyzed by 
flow cytometry. As reported previously (16), both immature 
and mature DC were negative for lymphoid markers, but 
expressed the mouse DC-restricted antigens DEC 205 and 
CDllc, and MHC class I and II. The IL-4-induced mature 
DC, that strongly stimulated naive allogeneic T cell prolifer-
ation in MLR, also expressed high levels ofCM (CD40, CDSO, 
and CDS6), but very low levels of the macrophage-associated 
markers F4/S0, CDllb, and CD32. By contrast, TGF{3-stim-
ulated immature DC that exhibited weak allostimulatory 
activity, expressed only low levels of CD40, CDSO, and CDS6 
(data not shown). 
The capacity of donor immature DC to prolong heart graft 
survival is markedly enhanced by anti-CD40L mAb, and de-
pendent on donor MHC class II expression. As shown in 
Figure la, the capacity of donor immature DC to prolong 
heart allograft survival when infused 7 days before trans-
plant, was strikingly enhanced by coadministration of anti-
CD40L mAb on day -7. Infusion of mature donor DC (prop-
agated in GM-CSF+ IL-4) 7 days before heart transplant 
resulted in accelerated graft rejection compared with un-
treated controls. Coadministration of anti-CD40L mAb re-
versed this effect partially, but not significantly (Fig. 1bl. 
Neither the mAb alone (Fig. lA) nor third-party immature 
DC <BALBIc; H-2d ) [median graft survival time 17 days 
(n=9), compared with 13 days in syngeneic immature DC-
pretreated controls (n=5)] affected graft survival signifi-
cantly. Control IgG reversed the effect of immature donor DC 
infusion (Fig. lA). The mechanism underlying this effect is 
unknown. Conceivably, the Ig may have opsonized or acti-
vated the donor DC leading to their enhanced elimination! 
host sensitization. 
Donor immature DC+anti-CD40L mAb inhibit anti-donor 
CTL activity orGIC and host spleen cells. We next examined 
the influence of immature donor DC+mAb treatment 7 days 
before cardiac transplantation on ex vivo indices of antidonor 
immune reactivity. Approximately equivalent numbers of 
cells, exhibiting similar phenotypic distribution were isolated 
from heart grafts of both experimental and control groups on 
days 8 and 14 posttransplant. Evaluation of specific anti-
donor CTL activity of freshly isolated GIC from the group 
pretreated with immature DC plus anti-CD40L on day 8 
posttransplant revealed a reduction of 30-50% in CTL activ-
ity in GIC compared with untreated, heart-grafted controls. 
By day 14, CTlJ activity in GIC was almost completely sup-
pressed in the experimental group, whereas it was main-
tained in controls (Fig. 2). 
Compared with GIC at the same time point, anti-donor 
CTL activity in spleens of graft recipients was very low on 
day S. However, a much higher level, similar to that seen in 
the graft, was detected in spleens of untreated animals on 
day 14_ These responses were suppressed to normal control 
values (low negligible CTL activity) in mice preconditioned 
with immature donor DC+anti-CD40L mAb. 
Inhibition of antidonor CTL responses is correlated with 
increased numbers of apoptotic cells within GIC and spleen T 
cell populations. We next compared the incidence of apopto-
tic cells detected by TUNEL staining, both in heart GIC 
pOPlliations {located in the myocardium and surrounding 
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FIGURE 1. A, Anti-CD40L mAb enhances the capacity of immature 
donor-derived DC to prolong vascularized cardiac allograft survival. 
Immature or mature DC were propagated from B10 <H-2b ) mouse 
bone marrow, as described in Materials and Methods, and injected 
i 2x 10°) i.v. either alone, or together with 200 f.Lg anti-CD40L mAb, 
i.p. into C3H (H_Zk) recipients, 7 days before B10 heart transplan-
tation (HTX) on day O. Control groups received either no treatment 
(PBS), anti-CD40L mAb. or normal rat IgG (isotype control) alone on 
day -7. B, Pretreatment with mature DC resulted in accelerated 
graft rejection, that was not reversed by mAb administration. Anti-
CD40L mAb pretreatment alone did not significantly affect allograft 
survival. Results obtained from groups of 6-19 mice. Immature 
DC+anti-CD40L versus immature DC+ IgG, P<O.OOl; immature 
DC+anti-CD40L versus anti-CD40L, P<O.Ol; immature DC+anti-
CD40L versus immature DC, P<O.Ol; immature DC versus PBS, 
P<O.01; mature DC versus PBS, P<O.Ol; mature DC+anti-CD40L 
versus PBS, P<O.05. 
vessels) and in the spleen of mice given immature donor DC 
plus anti-CD40L mAb, compared with untreated controls, or 
with mice given either immature DC, or mature DC alone. As 
shown in Figure 3, the incidence of apoptotic cells in the graft 
was increased in the combined treatment group, compared 
with that in animals given immature DC alone. The inci-
dence of apoptotic cells in graft infiltrates was strikingly 
reduced in mice given mature donor DC that rejected their 
grafts in an accelerated fashion (Fig. 3). Treatment with 
immature donor DC+anti-CD40L mAb also resulted in com-
paratively high incidence of apoptotic (Tl!NEL +) cells in. T 
cell areas and surrounding red pulp of reclplent spleen (FIg. 
4; Table 1). Spectrofluorometric assay of DNA fragmentation 
in spleen cell populations confirmed the high levels of apo-
ptotic activity in this group (Table 1). 
Enhancement of heart allograft survival by donor imma· 
ture DC+anti-CD40L mAb treatment is associated with in· 
creased microchimerism. To determine the relation between 
graft survival and microchimerism, donor I-Ab+ cells were 
identified and enumerated in host spleens at various times 
post transplant (days 0, 7, 14, and 100) (Fig. 5). I_Ab+ cells 
with DC morphology were readily detected on day 0 in the 
spleens of heart recipients pretreated with immature 
DC::!:anti-CD40L mAb. Compared with untreated, heart-
grafted controls, similar numbers of donor cells were detected 
in these groups at day 7. By day 14, the level of micro chimer-
ism had declined, except in the group given donor cells + mAb. 
in which it was sustained (Fig. 6A). Moreover, in the latter 
group, animals with beating grafts >100 days posttransplant 
exhibited the highest levels of microchimerism detected 
throughout the study (P<O.05, compared with values at all 
other time points) (Figs. 5 and 6B). 
Up·regulation of costimulatory molecule (CM) expression 
on donor-derived immature DC is not prevented by anti· 
CD40L mAb. Immature DC that are deficient in cell surface 
expression of CD80 and CD86 can prolong allograft survival, 
but fail to induce tolerance (16-18). The eventual rejection of 
the grafts may be due to "late" up-regulation of CM on the 
donor DC after presumed interaction with recipient T cells. 
Under these conditions, ligation of CD40 on DC and CD40L 
on activated T cells may result in up-regulated CM expres-
sion, with consequent T cell proliferation, and CTL genera-
tion. We therefore explored possible mechanisms involved in 
the enhancement of allograft survival by combined immature 
DC and anti-CD40L mAb therapy. We investigated CM ex-
pression on donor-derived DC in vitro and in situ, 7 days 
after their systemic infusion. In vitro studies showed that 
expression of CD40, CD80, and CD86 was increased signifi-
cantly by exposure of immature DC to allogeneic T cells for 
18-36 hr (Fig. 7). This up-regulation of CM expression was 
not prevented by adding anti-CD40L mAb (10 }.J.g/ml) at the 
start of culture (Fig. 7). The concentration of mAb used 
achieved maximal inhibition ofT cell proliferation (30-40%) 
in 72-hr primary MLR. This finding was confirmed in vivo by 
injecting immature donor DC (I-A b+, CD401o, CD801u• 
CD861o)::!:anti-CD40L mAb, and performing double immuno-
histochemical staining for donor MHC class II and CD86. As 
shown in Figure 8, more than 80% ofI-Ab+ cells in spleens of 
mice given immature DC+anti-CD40L mAb were also 
CD86+ 7 days after their injection (compared with only ap-
proximately 10% before injection). This indicated that ex-
pression of CD86 was up-regulated in host lymphoid tissue, 
despite the presence of anti-CD40L mAb, 
Immature DC+anti-CD40L mAb pretreatment reduces 
IL-2 production in the spleens of heart allograft recipients. 
Next, we investigated the possible role of IL-2 in relation to 
the apoptosis observed in lymphoid tissue of the graft recip-
ients, Because apoptosis of activated T cells may be attrib-
utable to insufficiency of IL-2 production, with consequent 
reduction in cell viability/growth, we investigated IL-2 pro-
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FIGURE 2. Cytotoxic activity of freshly isolated normal (C3H) heart nonparenchymal cells, heart graft-infiltrating cells (GIC), and recipient 
(C3H) spleen cells against target cells (EL4) expressing donor (BID) alloantigen (H_2b). A 4-hr slCr-release assay was used to determine 
cytotoxicity 8 or 14 days after organ transplantation. Treatment of heart graft recipients with immature DC + anti-CD40L mAb 7 days before 
heart transplantation (HTX) inhibited the a.nti-donor CTL response, both within the graft, and systemically. By day 14, these responses were 
profoundly suppressed. Cells were pooled from groups of eight normal or three transplanted animals. Results, calculated as described in 
Materials and Methods, are means:!: 1 SD, and are representative of two separate experiments . 
FIGURE 3. Detection ofTUNEL + apoptotic cells within BID cardiac allografts of untreated C3H mice or mice pretreated (day -7) with either 
immature donor-derived DC:!:anti-CD40L mAb, or mature donor DC. Results obtained on day 7 posttransplant, with the exception of bottom 
right (day 14). The comparatively high incidence of apoptotic cells seen in the graft-infiltrating cell (GIC) population of mice pretreated with 
immature donor DC+anti-CD40L mAb correlated with significant elevations (2-fold) in DNA fragmentation detected by spectrofluorometric 
assay in freshly isolated GIC compared with untreated controls 7 days post transplant (see Table 1) (magnification x 100). Counterstained 
with hematoxylin. 
duction in situ in the spleens of heart-allografted mice at 
various times (days 0, 7, and 14) posttransplant. Administra-
tion of immature DC reduced the number of IL-2+ cells and 
the intensity of IL-2 staining in T cell and red pulp areas 
compared with untreated graft recipients (Fig. 9), whereas in 
contrast, administration of mature donor DC 7 days before 
organ grafting increased the incidence of IL-2+ cells and the 
intensity ofIL-2 staining. The inhibitory effect of the imma-
ture cells was rendered more pronounced by coadministra-
tion of anti-CD40L mAb. Thus, the comparatively high inci-
dence of apoptotic cells of lymphoid tissue in the combination 
therapy group was correlated both with a reduction in local 
IL-2 production, and with comparatively high levels of donor 
DC microchimerism (or donor MHC class II+ cells). 
DISCUSSION 
These observations lend credibility to the hypothesis that 
clonal exhaustion-deletion oflymphocytes, linked to the pres-
ence of migratory donor leukocytes (including DC) is the 
seminal basis of organ allograft acceptance and of transplan-
tation tolerance generally (1-4). Different from the sponta-
neous tolerance induced by the liver in the same strain com-
bination (7), the prolonged survival of cardiac allografts 
required assistance by concomitant pretreatment with a 
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A. normal spleen B. untreated C.mature DC + mAb D. immature DC + mAb 
FIGURE 4. A-D, Detection of TUNEL + (apoptotic cells) in spleen T cell and red pulp areas of (A) normal C3H mice or (B-D) C3H recipients 
of BIO cardiac allografts 7 days posttransplant. Heart-transplanted animals were either Wltreated (B), pretreated (day -7) with mature 
donor-derived DC (C), or immature donor DC + anti-CD40L mAb (D). The comparatively high numbers of apoptotic cells seen in mice given 
immature donor DC+mAb CD) correlates with the 2- to 3-fold increase in apoptotic activity (DNA fragmentation) detected by spectrofluoro-
metric assay in spleen cells from this group, compared with Wltreated heart-grafted controls (Table 1). Pretreatment with donor mature DC, 
that accelerated graft rejection, was associated with an apparent reduction in the incidence of apoptotic cells in the spleen. Magnification: 
main, x 100, inset, x 400. Counterstained with hematoxylin. 
TABLE 1. Recipient pretreatment with immature donor DC+anti-
CD40L mAb markedly increases the incidence of apoptotic cells in 
graft-infiltrating and spleen cell populations 
Cells Treatment % apoptotic 
cells 
GICO Normal 5.5:!:2.3b 
Untreated 14.8:!:2.6 
Mature DC 7.9:t1.5 
Immature DC 18.6:!:3.8 
Immature DC+anti-CD40L mAb 30.6:!:2.7 
Spleen cells Normal 4 .5:t2.7c 
Untreated 14.8:t5.6 
Mature DC 7.2:!:2.4 
Immature DC 18.2:!:6.2 
Immature DC+anti-CD40L mAb 32.4:!:8.6 
o GIC, Graft-infiltrating cells. 
b Determined by TUNEL staining. 
C Determined by spectrofluorometric DNA fragmentation assay. 
C3H mice received either no treatment, or 2x 106 mature BIO DC, 
or 2x 106 immature BIO DC:t200 J.Lg anti-CD40L mAb, 7 days before 
heterotopic vascularized B 10 heart transplant. Seven days post-
transplant, heart graft-infiltrating cells were isolated, as described 
in Materials and Methods, and stained for apoptosis by TUNEL. The 
incidence of TUNEL + cells in counts of 500 cells was determined by 
a "blinded" observer. Spleen cell suspensions were prepared at the 
same time, cultured overnight in complete medium, and DNA frag-
mentation determined by spectrofluorometric assay, as described in 
Materials and Methods. Results as means:t I SD obtained from 
groups of three animals. 
highly targeted immunosuppressant (CD40L mAb) and an 
additional source of modified donor cells . 
The supplementary cells were MHC class 11+ donor DC 
that had propagated under conditions that inhibit their ex-
pression of the CM molecules CD40, 80, and 86, and reduce 
their immunogenicity (16, 23). The second component of pre-
treatment was with the CD40L mAb, which is directed 
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FIGURE 5. Quantitation of microchimerism (donor MHC class II+ 
cells) in spleens of C3H recipients of B 10 cardiac allografts pre-
treated (day -7) with either immature donor-derived DC:tanti-
CD40L mAb, or mature donor DC. The total number of donor MHC 
class II+ (IA b+ ) cells in cryostat sections of spleens at three separate 
levels, was determined under high power examination (X40 objec-
tive) for each of three mice in each group, at each time point. Results 
are expressed as mean number ofIAb + cells per low power field:!: 1 
SD. 
against the CD40L up-regulated by activated T cells (24). 
This mAb is thought to act by blocking CD40 receptor en-
gagement of CD40L by DC, B cells, and other antigen-pre-
senting cells (APC), thus preventing up-regulation ofB7 and 
other CM (24-27) . A possible explanation for the previously 
reported efficacy of the two modalities in combination (16) 
was that the CD40L mAb perpetuated counter-regulatory 
(i.e ., proapoptotic) signals from DC (21). Instead, the infused 
DC differentiated after their infusion. This was evident from 
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FIGURE 6. A, Microchimerism (donor MHC 
class II+ cells) detected by immunohistochem-
istry 14 days posttransplant, in spleens of 
C3R recipients of B10 cardiac allograft pre-
treated (day -7) with either immature donor-
derived DC:!:anti-CD40L mAb, or mature do-
nor DC. Whereas infusion of donor mature 
DC 7 days before heart transplant resulted in 
reduced levels of microchimerism, pretreat-
ment with immature donor DC, especially in 
combination with anti-CD40L mAb, resulted 
in the highest observed levels of donor class 
II+ cells. B, This effect became more pro-
nounced with time posttransplant, and the 
highest incidences of microchimerism were 
detected in animals with long-surviving 
grafts, 100 days posttransplant. Anti-CD40 
mAb administration alone did not affect the B 
incidence of donor MRC class II+ cells com-
pared with PBS controls. Magnification, 
Ax200, B X100 (left); X1000 (right). 
A 
their up-regulation of B7.2 (CD86), consistent with recently 
reported observations in a cardiac transplant model in which 
resting B cells were the APC (26), and also with the earlier 
demonstration that blockade of the CD40 pathway did not 
inhibit B7 transcripts in murine heart allografts (27). 
The prolonged acceptance of cardiac allografts in the pre-
treated animals (> 100 days in 40% ofrecipients) appeared to 
occur in essentially the same sequential steps as the toler-
ance induced spontaneously by liver allografts. The first 
phase was acute donor-specific clonal activation of CTL after 
migration of graft-derived donor leukocytes and the infused 
donor-derived DC to host lymphoid organs. This was suc-
ceeded by apoptosis associated with IL-2 deficiency (that may 
also reflect T cell anergy) in the microenvironment of the 
activated cells. Ongoing studies in OUr laboratory using lim-
iting dilution analysis will provide an accurate estimate of 
the frequency of donor-reactive CTL and of IL-2-producing 
cells. The apoptosis at the graft site was a direct reflection of 
the apoptosis in the host spleen. Finally, a mOre or less stable 
state was established with low level (micro)chimerism and 
residual low grade antigraft activity in the lymphoid organs. 
The persistence of chimerism after transplantation has 
been explained by the presence of precursor an~ m cell~ in 
the passenger l~ocyte~orgIlns (8, 2~ 29)) The continu-
ous presence of donor-derived leukocytes in lymphoid areas, 
\ 
Or their leakage there from nonlymphoid repositories has 
been suggested as an explanation for the maintenance of 
Iclonal exhaustion (J, 30, 31), comparable to the stable equi- ) 
,librium between destructive and nondestructive immunity 
described in an analogous model of autoimmune diabetes " 
mellitus (32,33). This view is consistent with the historical 
ihYPothesis that acquired allograft tolerance is a dynamic antigen-dependent state (34, 35). The experiments of Ehl et aL (5) have demonstrated that the migratory donor leuko-
cytes (i .e., microchimerism) rather than the peripheral graft 
'.are the~l'iti{!aLs.ource of this antigen. '----
Before the presence of persistent chimerism in organ re-
cipients was recognized, allograft acceptance was explained 
by T cell receptor ligation of host lymphocytes by organ 
parenchymal cells that are incapable of delivering an effec-
tive costimulatory signal. The postulated result was antigen-
specific clonal "silencing" (anergy) (36-41), defined by the 
restoration of T cell reactivity when IL-2 is added to host 
lymphocytes in vitro Or in vivo. We have argued instead that 
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FIGURE 7. Up-regulation of costimulatory molecule expression on immature DC after exposure to allogeneic T cells is not inhibited in the 
presence of anti-CD40L mAb. Immature BIO (H-2 b ) DC were cocultured with purified allogeneic naive C3H (B_2") T cells mc: T cells = 1:2) 
for 18 hr (CD40, CD86) or 36 hr (CD80) in the absence or presence of anti-CD40L mAb (10 p.glmn. Expression of CD40. 80. and 86 was then 
determined on gated cells by flow cytometric analysis (T cells were gated out by staining with anti-CD3 mAbJ. Open profiles denote Ig isotype 
controls, 
both the culmination of the afferent phase and the effector 
response leading to antigen-specific nonreactivity occur in 
the host lymphoid organs where antigen-reactive T cells are 
activated within the first few days and differentiate to effec-
tor cells (1). It is in these organized lymphoid collections 
where DC and other APCs that have captured and processed 
antigen present the peptide fragment of the antigen to anti-
gen-specific T cell receptors in the context of their up-regu-
lated host MHC complex peptide. The lymphoid organs pro-
vide the unique architectural structure and cellular milieu in 
which factors that constitute the necessary immunogenic-
tolerogenic environment are present in abundance; e.g .• cy-
tokines. other molecules, cell to cell proximity, and homing 
mechanisms that subserve transport of the antigen to the 
lymphoid organs (31, 42). 
Reverse delivery from the lymphoid organs to the periph-
eral organ of antigen-activated CTL that already have re-
ceived a death signal is assured by chemokines and other 
mechanisms that ensure homing of these effector cells to the 
allograft site (43). The rapidity with which this occurs is 
evident in our experiments from the essentially equal rate of 
apoptosis in the host cells infiltrating the graft and in the 
spleen cells (Table 1). More than 30% oflymphocytes in both 
locations were undergoing apoptosis at the peak period of 8 
posttranspla~t days (Table 1). Because the spleen constitutes 
only a fraction of the organized host lymphoid tissue (all of 
which share the same basic architecture and function) to 
which donor leukocytes migrate (6, 8,10,11,38,39,44) the 
magnitude of the cumulative apoptosis in the global lym-
phoid system can be reasonably inferred. Indeed, the com-
paratively high incidence of apoptotic lymphoid cells in the 
spleens of animals given donor cells + anti-CD40L mAb was 
also observed in the mesenteric lymph nodes (Lu L, Thomson 
AW, unpublished observations). The presence of an organ 
allograft is not essential for the deletion by apoptosis de-
scribed herein, as has been shown by Sykes et a1. (45) in 
mouse recipients of bone marrow allografts using treatment 
with sublethal total body irradiation and CD40L mAb and 
CTLA4Ig. 
The molecular and cellular pathways responsible for the 
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MHC class II CD86 MHC class II + CD86 
FIGURE 8. Infusion of immature donor DC+anti-CD40L mAb 7 days before transplant does not result in inhibition of B7 (CD86) molecule 
expression on donor cells in spleens of allogeneic recipients 7 days postinfusion. Sections were stained by two-color immunohistochemistry, 
for either donor MHC class II (red), or B7-2 (CD86) (green), or both molecules (yellow denotes positive cells) as described in Materials and 
Methods. Animals received either immature DC+anti-CD40L mAb (upper row), or immature DC alone. Results are representative of groups 
of three mice in each treatment group. Magnification X400. 
dO 
d7 
d14 
Mature DC hnmatureDC 
hnmatureDC 
+aCD40L 
FIGURE 9. IL-2 synthesis detected by immunohistochemical staining in the spleen of heart allograft recipients, at various times post heart 
transplant (HTX). Whereas infusion of donor mature DC 7 days before HTX was associated with high levels of IL-2 expression (blue staining) 
on day 0, 7, and 14 posttransplant, animals given immature donor DC did not exhibit strong staining for IL-2 until 7 days post-HTX. Infusion 
of immature donor DC+anti-CD40L mAb suppressed IL-2 production at each time point examined. Magnification x 100. 
_ ... _--------_._----
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apoptosis are incompletely understood, but may include 
those of replicative exhaustion (11, 12) [e.g., telemere short-
ening when the Hayflick proliferative limit is exceeded (46)]' 
and FaslFas ligand or other mechanisms of programed cell 
death (13, 21). Indeed whatever the precise explanation, it 
has been shown that endogenous cytokines classically asso-
ciated with immune activation and rejection (e.g., IL-2, in-
terferon-y, and IL-12) can not be removed from the immuno-
logical response system by gene deletion or other means 
without loss of toler ogene sis (47-52). Recently, IL-2 has been 
shown to enhance activation-induced cell death mediated by 
the Fas pathway in CD4 + cells (53). It also has been estab-
lished in a variety of models that the clonal exhaustion-
deletion is more rapidly accomplished with larger amounts of 
antigen (reviewed in Ref. 1). This accounts for the unusual 
tolerogenicity of the leukocyte-rich liver and explains why 
adjunct donor leukocytes or purified donor antigen facilitate 
the engraftment in most experimental transplantation mod-
els (5) including several used to test the efficacy of CD40L 
mAb (25, 26, 54-57). 
The collective evidence from in vivo research in transplan-
tation immunology has shown that if donor cells from the 
allograft (or cells infused separately) do not reach host lym-
phoid organs, a specific cytotoxic T cell response is either not 
induced or cannot be maintained, thereby precluding the 
succeeding step of donor specific tolerance (1, 30, 31, 58). 
With activation, the transition from destructive immunity to 
nonreactivity appears to occur by the final common pathway 
described, the diverse cellular and molecular targets of the 
immunosuppressants notwithstanding (1). Consequently, 
the clinical applicability of drugs under preclinical develop-
ment ultimately hinges on their relative efficacy, toxicity, 
and compatibility with other agents. 
It is noteworthy that immunosuppression is a two-edged 
sword, controlling destructive consequences of immunity, but 
potentially eroding the basis of allograft acceptance, i.e., 
immune activation. For example, the administration of adre-
nal cortical steroids prevents spontaneous tolerance in a liver 
transplant model (11), and of current interest, cyclosporine 
appears to abrogate the tolerogenic effects of costimulatory 
blockade (57). 
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